Mostrar el registro sencillo del ítem
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis
dc.contributor.author | Qureshi, Rehana | |
dc.contributor.author | Picón Ruiz, Manuel | |
dc.contributor.author | Díaz Ruano, Ana Belén | |
dc.date.accessioned | 2023-01-12T13:25:49Z | |
dc.date.available | 2023-01-12T13:25:49Z | |
dc.date.issued | 2022-11-15 | |
dc.identifier.citation | Rehana Qureshi... [et al.]. Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis, Cell Reports, Volume 41, Issue 7, 2022, 111672, ISSN 2211-1247, [https://doi.org/10.1016/j.celrep.2022.111672] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/78958 | |
dc.description.abstract | Recent work showed that the dominant post-menopausal estrogen, estrone, cooperates with nuclear factor kB (NF-kB) to stimulate inflammation, while pre-menopausal 17b-estradiol opposes NF-kB. Here, we show that post-menopausal estrone, but not 17b-estradiol, activates epithelial-to-mesenchymal transition (EMT) genes to stimulate breast cancer metastasis. HSD17B14, which converts 17b-estradiol to estrone, is higher in cancer than normal breast tissue and in metastatic than primary cancers and associates with earlier metastasis. Treatment with estrone, but not 17b-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT. Estrone:ERa recruits CBP/p300 to the SNAI2 promoter to induce SNAI2 and stimulate an EMT, while 17b-estradiol:ERa recruits co-repressors HDAC1 and NCOR1 to this site. Present work reveals novel differences in gene regulation by these estrogens and the importance of estrone to ER+ breast cancer progression. Upon loss of 17b-estradiol at menopause, estrone-liganded ERa would promote ER+ breast cancer invasion and metastasis. | es_ES |
dc.description.sponsorship | United States Department of Health & Human Services | es_ES |
dc.description.sponsorship | National Institutes of Health (NIH) - USA 1R01CA210440-01A1 | es_ES |
dc.description.sponsorship | Florida Breast Cancer Foundation | es_ES |
dc.description.sponsorship | Breast Cancer Research Foundation | es_ES |
dc.description.sponsorship | Susan G. Komen Breast Cancer Foundation PDF16380958 | es_ES |
dc.description.sponsorship | Ministry of Science and Innovation, Spain (MICINN) Spanish Government PID2020-119502RJ-I00 | es_ES |
dc.description.sponsorship | UGR-FEDER program E-CTS654-UGR20 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cell Press | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.1016/j.celrep.2022.111672 | |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |